Table 1.

Effect of Everolimus Treatment on PFS

		Subgroups
Variable		PD (n=16)	Non-PD (n=8)	P value⁎
Treatment	Everolimus+chemotherapy	0 (0%)	5 (62.5%)	.001
	Chemotherapy	16 (100%)	3 (37.5%)
Baseline PIK3CA mutation	Yes	8 (50%)	5 (62.5%)	.68
PIK3CA mutation frequency	Increased	9 (56.25%)	0 (0%)	.002
	Decreased	1 (6.25%)	5 (62.5%)

^⁎P value was calculated using Fisher’s exact test (n<5) for subgroup comparison between the indicated subgroups.